☆ 4.6 Article

Antibody Response to SARS-CoV-2 Infection and Vaccination in COVID-19-naive and Experienced Individuals

VIRUSES-BASEL (2022)

Related references

Note: Only part of the references are listed.

Article Immunology

Necessity of Coronavirus Disease 2019 (COVID-19) Vaccination in Persons Who Have Already Had COVID-19

Nabin K. Shrestha et al.

Summary: Both previous infection and vaccination provide substantial protection against COVID-19. Vaccination of previously infected individuals does not provide additional protection against COVID-19 for several months, but after that provides significant protection at least against symptomatic COVID-19. Individuals previously infected with COVID-19 are substantially protected against COVID-19 for several months in the absence of vaccination. Beyond that time, vaccination protects against symptomatic COVID-19 among those previously infected, probably by boosting of waning natural immunity.

CLINICAL INFECTIOUS DISEASES (2022)

Add to Collection

Article Cell Biology

Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2-experienced individuals

Marie Samanovic et al.

Summary: COVID-19 vaccines are crucial in ending the pandemic, but the immune responses induced by mRNA vaccines may differ in individuals who had recovered from COVID-19. The study found that both groups exhibited robust cytotoxic T cell responses after the second dose of the vaccine. However, individuals with no prior COVID-19 infection had increasing humoral and antigen-specific antibody-secreting cell responses after each dose, while those who had recovered from COVID-19 showed strong initial responses that did not further enhance after the second dose.

SCIENCE TRANSLATIONAL MEDICINE (2022)

Add to Collection

Article Public, Environmental & Occupational Health

COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021

Tomás M. León et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)

Add to Collection

Article Infectious Diseases

Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021

Kamal Abu Jabal et al.

Summary: An analysis of 514 Israeli healthcare workers showed that the BNT162b2 mRNA COVID-19 vaccine had similar immunogenicity by ethnicity and sex, but decreased with age. Individuals with prior COVID-19 infection had significantly higher antibody titres compared to those who were naive, regardless of pre-vaccination IgG levels.

EUROSURVEILLANCE (2021)

Add to Collection

Article Multidisciplinary Sciences

Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity

Carolina Lucas et al.

Summary: This study found that individuals previously infected with the virus had higher antibody titres post-vaccination compared to those who were uninfected, but both groups reached comparable levels of neutralization responses to the ancestral strain after the second vaccine dose. Comprehensive analysis of 16 locally circulating SARS-CoV-2 variants revealed varying degrees of reduction in neutralization capacity associated with specific mutations in the spike gene, suggesting vaccine boosters as a relevant future strategy to counteract the impact of emerging variants on antibody neutralizing activity.

NATURE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Shuo Feng et al.

Summary: Defined levels of SARS-CoV-2-specific binding and neutralizing antibodies elicited by the COVID-19 vaccine were identified as correlates of protection against symptomatic infection. Higher levels of immune markers were correlated with a reduced risk of symptomatic infection. The data can be used to extrapolate efficacy estimates to new populations.

NATURE MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2

Saman Saadat et al.

Summary: This study compared the titers of binding and neutralizing antibodies in healthcare workers previously infected with SARS-CoV-2 after receiving a single dose of mRNA coronavirus vaccine.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Letter Medicine, General & Internal

Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals

Charlotte Manisty et al.

LANCET (2021)

Add to Collection

Letter Medicine, General & Internal

Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine

Maria Prendecki et al.

LANCET (2021)

Add to Collection

Review Infectious Diseases

What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2

Susanne H. Hodgson et al.

Summary: The development of a vaccine for the novel coronavirus is crucial to prevent the spread of the pandemic and reduce disease mortality. The efficacy endpoint is protection against severe disease and death, but evaluating this in phase 3 clinical trials poses challenges.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Letter Medicine, General & Internal

Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine

Florian Krammer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern

Rishi R. Goel et al.

Summary: This study found that immune memory to SARS-CoV-2 and its variants remains robust for at least 6 months after mRNA vaccination, with antibodies declining but still detectable in most individuals. mRNA vaccines also induced functional memory B cells and antigen-specific T cells, with recall responses primarily increasing antibody levels in individuals with preexisting immunity.

SCIENCE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

Matthew McCallum et al.

Summary: The study identifies 41 human monoclonal antibodies that recognize the N-terminal domain of the SARS-CoV-2 spike protein and exhibit strong neutralizing activity. These antibodies inhibit cell-to-cell fusion, activate effector functions, and protect animals from virus challenge, highlighting the importance of NTD-specific neutralizing antibodies for protective immunity and vaccine development. Several SARS-CoV-2 variants with mutations in the NTD supersite suggest ongoing selective pressure on the virus.

CELL (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2

Joseph E. Ebinger et al.

Summary: Virus-specific antibody levels after a single dose of the BNT162b2 vaccine in individuals previously infected with SARS-CoV-2 are similar to levels after two doses of the vaccine in infection-naive individuals. Post-vaccine symptoms were more prominent for those with prior infection after the first dose, but symptomology was similar between groups after the second dose.

NATURE MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection

Leonidas Stamatatos et al.

Summary: The study found that vaccination of both previously infected individuals and those who were not infected resulted in increased neutralizing antibody titers, with previously infected individuals showing a greater boost in neutralizing titers. Vaccination of naive individuals also elicited cross-neutralizing responses, but at lower titers.

SCIENCE (2021)

Add to Collection

Article Multidisciplinary Sciences

Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection

Ge Song et al.

Summary: This study examines the impact of pre-existing immunity to seasonal endemic coronaviruses on antibody responses to SARS-CoV-2, finding weak evidence of pre-existing cross-reactive serum antibodies in pre-pandemic donors, but evidence of pre-existing cross-reactive memory B cells activated during SARS-CoV-2 infection. Monoclonal antibodies show varying degrees of cross-reactivity with betacoronaviruses, and one neutralizing antibody specific to the S2 subunit of the S protein is identified, suggesting that pre-existing immunity to endemic coronaviruses should be considered in evaluating antibody responses to SARS-CoV-2.

NATURE COMMUNICATIONS (2021)

Add to Collection

Review Immunology

Antibody Responses in COVID-19: A Review

Mateo Chvatal-Medina et al.

Summary: The SARS-CoV-2 continues to spread as a severe pandemic, with variable seroprevalence rates worldwide and higher rates among health workers. The cross-neutralizing response between SARS-CoV and SARS-CoV-2 is controversial, and the use of convalescent plasma has shown uncertain results. Cellular immunity plays a crucial role in resolving the infection.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Immunology

Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals after mRNA vaccination

Rishi R. Goel et al.

Summary: mRNA vaccines exhibit robust serological and cellular priming, with naïve individuals requiring two doses for optimal antibody responses, especially against the B.1.351 variant. Memory B cells specific for spike protein and RBD were efficiently primed by vaccination, while recovered individuals showed significant boosting after the first dose, correlating with preexisting memory B cell levels. Identifying distinct responses based on prior SARS-CoV-2 exposure suggests that recovered subjects may only need one vaccine dose for peak responses, which can inform vaccine distribution strategies in resource-limited settings.

SCIENCE IMMUNOLOGY (2021)

Add to Collection

Letter Medicine, General & Internal

Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273

Deborah Steensels et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Multidisciplinary Sciences

Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates

Kizzmekia S. Corbett et al.

Summary: In nonhuman primates (NHPs), vaccination with mRNA-1273 induces dose-dependent antibody responses, leading to a significant reduction in viral replication post SARS-CoV-2 challenge. Replication of the virus correlates strongly with antibody levels and neutralizing activity, with lower levels required in the lower airway than in the upper airway. Passive transfer of mRNA-1273-induced IgG is sufficient to provide protection, indicating that humoral immune responses induced by mRNA-1273 vaccine are effective against SARS-CoV-2 in NHPs.

SCIENCE (2021)

Add to Collection

Article Multidisciplinary Sciences

Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history

Thomas W. McDade et al.

Summary: The two-dose mRNA vaccines against SARS-CoV-2 are effective in preventing COVID-19 infection, but there is a decline in antibody levels and reduced neutralization of emerging variants three months post-vaccination, indicating the need to identify correlates of clinical protection for booster vaccination timing and indications.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Cell Biology

Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells

Kristen W. Cohen et al.

Summary: The study reveals that COVID-19 patients have durable broad-based immune responses, including the continuous generation of antibodies, memory B cells, and polyfunctional T cells, which help to rapidly generate antibody responses against virus re-exposure or vaccination.

CELL REPORTS MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Nanshan Chen et al.

LANCET (2020)

Add to Collection

Article Multidisciplinary Sciences

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Peng Zhou et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Daniel Wrapp et al.

SCIENCE (2020)

Add to Collection

Article Microbiology

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Michael Letko et al.

NATURE MICROBIOLOGY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Markus Hoffmann et al.

CELL (2020)

Add to Collection

Article Multidisciplinary Sciences

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Jun Lan et al.

NATURE (2020)

Add to Collection

Article Multidisciplinary Sciences

Structural basis of receptor recognition by SARS-CoV-2

Jian Shang et al.

NATURE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

A serological assay to detect SARS-CoV-2 seroconversion in humans

Fatima Amanat et al.

NATURE MEDICINE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Antibody responses to SARS-CoV-2 in patients with COVID-19

Quan-Xin Long et al.

NATURE MEDICINE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies

Christopher O. Barnes et al.

CELL (2020)

Add to Collection

Article Multidisciplinary Sciences

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Lihong Liu et al.

NATURE (2020)

Add to Collection

Letter Medicine, General & Internal

Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19

F. Javier Ibarrondo et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

An mRNA Vaccine against SARS-CoV-2-Preliminary Report

L. A. Jackson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Multidisciplinary Sciences

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

Xiangyang Chi et al.

SCIENCE (2020)

Add to Collection

Article Multidisciplinary Sciences

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

Ching-Lin Hsieh et al.

SCIENCE (2020)

Add to Collection

Article Cell Biology

COVID-19 diagnostics in context

Ralph Weissleder et al.

SCIENCE TRANSLATIONAL MEDICINE (2020)

Add to Collection

Review Biotechnology & Applied Microbiology

Coronavirus disease 2019-Historical context, virology, pathogenesis, immunotherapy, and vaccine development

Sayeh Ezzikouri et al.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2020)

Add to Collection

Article Medicine, General & Internal

A history of herd immunity

David Jones et al.

LANCET (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Seasonal coronavirus protective immunity is short-lasting

Arthur W. D. Edridge et al.

NATURE MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Edward E. Walsh et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Multidisciplinary Sciences

Substantial underestimation of SARS-CoV-2 infection in the United States

Sean L. Wu et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Article Immunology

Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients

Anita S. Iyer et al.

SCIENCE IMMUNOLOGY (2020)

Add to Collection

Article Medicine, Research & Experimental

Convalescent plasma anti SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization

Eric Salazar et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

Add to Collection

Review Immunology

Humoral Responses and Serological Assays in SARS-CoV-2 Infections

Yannick Galipeau et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Article Immunology

Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome

Katharina Roltgen et al.

SCIENCE IMMUNOLOGY (2020)

Add to Collection

Article Multidisciplinary Sciences

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Ania Wajnberg et al.

SCIENCE (2020)

Add to Collection

Article Immunology

Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients

Nisreen M. A. Okba et al.

EMERGING INFECTIOUS DISEASES (2020)

Add to Collection

Article Immunology

Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients

Baweleta Isho et al.

SCIENCE IMMUNOLOGY (2020)

Add to Collection

Article Biochemical Research Methods

Development of a bead-based immunoassay using virus-like particles for detection of alphaviral humoral response

Keersten M. Ricks et al.

JOURNAL OF VIROLOGICAL METHODS (2019)

Add to Collection

© Peeref 2019-2024. All rights reserved.